BioCentury
ARTICLE | Clinical News

Tau Therapeutics preclinical data

May 5, 2014 7:00 AM UTC

In mouse xenograft models of K-Ras ( KRAS)-mutant pancreatic ductal adenocarcinomas, combination treatment with mibefradil plus trametinib led to greater inhibition of tumor growth compared to either treatment alone. Additionally, combination treatment led to near complete growth inhibition of KRAS-mutant tumors previously resistant to chronic trametinib therapy. Data were presented at the American Association for Cancer Research meeting in San Diego. ...